Fig. 1: MGO-treatment induces motor dysfunction, cognitive impairment, olfactory, and colonic disturbances in Thy1-aSyn mice.
From: Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes
Wild-type littermate (WT) and Thy1-aSyn transgenic (Tg) mice received an intracerebroventricular (ICV) injection of MGO or vehicle (PBS) at 16 weeks of age. Behavioral testing started 4 weeks post surgery. Plot representations of: pole test—a time to turn down, b time to climb down, c total time; rotarod—d stationary protocol, e acceleration protocol; f hindlimb clasping score; g fecal pellet production; block test—h time sniffing novel scent; Y maze test—i time on novel arm, j number of entries, k alternative behavior. At least n = 5 in all groups, data in all panels are average, with error bars representing standard deviation, Ordinary one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired two-tailed t-test with equal SD, #p < 0.05.
